Table 2.

Response to BDP or BDP+BUD Treatment for UGI aGVHD at Days +28 and +200 after Treatment Start

Variable	BDP(n = 76)	BDP+BUD (n = 81)	P Value
Response at day 28, n (%)			.2
CR	40 (53)	54(67)
PR	8(10)	8(10)
Failure	28 (37)	18(22)
Not evaluable*	0	1(1)
Response at day 200, n (%)			.2
CR	26 (34)	37 (46)
PR	2(3)	2(2)
Failure	31(41)	33 (41)
Not evaluable†	17(22)	9(11)
Treatment duration, d, median (range)‡	96(7–816)	225(10–1176)	<.0001

Significant P values (<.05) are in bold type.

^*Data missing.

^†22 were dead at day 200, and 4 were lost to follow-up.

^‡Patients with treatment duration <28 days (n = 6 patients in the BDP group and 8 in the BDP+BUD group) experienced CR, treatment failure with requirement of other additional IS agent, or death before the day 28 evaluation. All patients who achieved CR with short-course therapy maintained the CR through the day 200 evaluation.